



BioSystems International Licences Northeastern University Technology for Biomarker Discovery

Evry, France – March 10, 2006 – BioSystems International and Northeastern University (Boston MA) announce that they have signed a Licence Agreement for The University's "Monoclonal antibody based biomarker discovery and development platform."

BioSystems International (BSI) discovers and validates biomarkers through partnerships with pharmaceutical, biotechnology and diagnostics companies and in-house research programs or academic collaborations. BSI merges pharmaceutical and diagnostics industry experience with leading scientific and technology expertise in immunology, proteomics, genomics, separation science, micro/nanoscale analysis and bioinformatics.

The monoclonal antibody based biomarker discovery and validation platform was developed by scientists at Pfizer Fresnes Laboratories and Northeastern University. Pfizer retains rights to use the technology for its programs and transferred all other rights to Northeastern University. Now, Northeastern University grants BSI an exclusive, world-wide license for biomarker and drug target discovery, validation, development and commercialization for medical and all other commercial applications, including veterinary, agricultural, food industry and biohazard fields. The terms of the agreement are not disclosed.

According to Prof. Barry Karger, James A. Waters Chair of Analytical Chemistry at Northeastern University, director of the Barnett Institute, and co-founder of BSI, *"The licensed technology that has been developed offers a major opportunity to discover and validate trace level disease specific biomarkers. BSI will exploit its power in the biomedical and pharmaceutical domain while the Barnett Institute will advance the technology."*

BSI's objective is to establish a new standard in the research and discovery of biomarkers suitable for clinical development of drugs and the development of diagnostic tests. The technology platform and expertise of the BioSystems International team permits the identification of disease or pathology-specific biomarkers within a short time frame, compatible with the constraints of drug development. Biomarkers, which make it possible to diagnose a disease, follow its progression or evaluate drug efficacy are crucial for the pharmaceutical industry. They are expected to result in a significant reduction in the cost and duration of clinical trials and improve the clinical follow-up of patients.

According to Laszlo Takacs, President and CEO of BioSystems International, **"With the monoclonal antibody based biomarker discovery and validation technology license, BSI's already rich intellectual property portfolio is significantly enhanced. Now we have a strong position to secure technology advantage over competition in the area of monoclonal antibody based proteomics and its application in the healthcare industry. BSI is looking forward to applying the licensed and in-house technologies to establish partnerships and internal programs for the discovery of novel cancer and chronic disease diagnostics."**

About BioSystems International:

The mission of BioSystems International is to "Bring biomarkers to the bedside".

BioSystems International ("BSI"), headquartered in Evry, France, operates one research laboratory in France (Genopole Evry) and one in Hungary (University of Debrecen) and is currently in late-phase contract negotiations with several international pharmaceutical companies

Since it was founded in May 2004, BSI has raised funds from Societe Generale Asset Management and received grants from the Hungarian Ministry of Education and the French Innovation Agency (Oseo Anvar).

BSI's discovery technology and unique development methods combine high throughput monoclonal antibody technology, mass spectrometry and genome research technologies. It allows BSI to achieve the targeted and quantitative analysis of virtually all proteins in body fluids of treated or untreated patient groups and control subjects with the sensitivity and precision of ELISA assays faster than any other existing technologies. BSI builds

a streamlined strategy to identify and validate the most promising biomarkers via a process that includes confirmation of clinical relevance on BSI's patient cohorts or clinical material from large Phase II and Phase III clinical trials of its partners.

www.biosys-intl.com

About Northeastern:

Northeastern University, located in the heart of Boston, Massachusetts, is a world leader in practice-oriented education and recognized for its expert faculty and first-rate academic and research facilities. Northeastern integrates challenging liberal arts and professional studies with the nation's largest cooperative education program. Through co-op, Northeastern undergraduates alternate semesters of full-time study with semesters of paid work in fields relevant to their professional interests and major, giving them nearly two years of professional experience upon graduation. The majority of Northeastern graduates receive a job offer from a co-op employer. Cited for excellence four years running by U.S. News & World Report, Northeastern has quickly moved up into the top tier rankings-an impressive 35 spots in four years. In addition, Northeastern was named a top college in the 2006 edition of the Princeton Review's annual "Best Colleges" issue. For more information, please visit <http://www.northeastern.edu>.

Contact :

François Liebaert

Vice President Business Development & Finances

BioSystems International

4, rue Pierre Fontaine

91058 Évry cedex - France

+33 1 60 87 89 32

francois.liebaert@biosys-intl.com

www.biosys-intl.com

Laura Shea

For Northeastern University

617-373-5427

l.shea@neu.edu